Signal Explorer

Secondary Endpoint Mentioned Clinical Trial Result Combination Therapy Mentioned Indication Expansion

Interim Data Positive Publication Positive Patient Retention High Checkpoint Inhibitor Program Kol Endorsement Expanded Access Program Active Safety Differentiated Fda Aligned

Clinical Trial Result Secondary Endpoint Mentioned Combination Therapy Mentioned

Interim Data Positive Patient Retention High Fda Aligned Enrollment Ahead Of Schedule Kol Endorsement Checkpoint Inhibitor Program Publication Positive Fast Track Designation Received Expanded Access Program Active Safety Differentiated

Secondary Endpoint Mentioned Combination Therapy Mentioned Clinical Trial Result Indication Expansion

Checkpoint Inhibitor Program Interim Data Positive Publication Positive Fda Aligned Priority Review Or Pdufa Disclosed Board Committee Member Listing

Secondary Endpoint Mentioned Clinical Trial Result Combination Therapy Mentioned

Interim Data Positive Patient Retention High Expanded Access Program Active Enrollment Ahead Of Schedule Fda Aligned Checkpoint Inhibitor Program Publication Positive Fast Track Designation Received

Combination Therapy Mentioned Secondary Endpoint Mentioned Clinical Trial Result Indication Expansion Lead Asset Progress

Interim Data Positive Enrollment Ahead Of Schedule Board Committee Member Listing Patient Retention High Checkpoint Inhibitor Program Safety Differentiated Publication Positive Kol Endorsement Expanded Access Program Active

Form S3 Shelf Registration Disclosure Amendment Modification Waiver Clause Fcpa Compliance Representation Sanctions Compliance Representation Hazardous Materials Definition Hipaa Fraud Abuse Laws Disclosure Registration Rights Piggyback Provision Corporate Organization And Standing Representation Conflicted Defense Counsel Provision Confidential Information Return Obligation

Financing Activities Cash Flow Disclosure Cash Flow Statement Investing Activities Fair Value Hierarchy Reconciliation Disclosed Net Loss Reported Checkpoint Inhibitor Program Institutional Investment Equity Plan Board Approval Conditional On Shareholder Vote Ipo Or Capital Raising Completion Publication Positive Equity Plan Share Reserve Disclosure Expanded Access Program Active Shares Outstanding Disclosure

Clinical Trial Result Combination Therapy Mentioned Indication Expansion

Net Loss Reported Checkpoint Inhibitor Program Interim Data Positive Kol Endorsement Patient Retention High Burn Rate Controlled Publication Positive Expanded Access Program Active Fast Track Designation Received

Combination Therapy Mentioned Clinical Trial Result Indication Expansion Patient Enrollment Velocity

Volume Inflecting Reimbursement Improving

Safety Differentiated Interim Data Positive Geographic Footprint Disclosure Board Committee Member Listing Kol Endorsement Patient Retention High Priority Review Or Pdufa Disclosed Checkpoint Inhibitor Program Publication Positive Fda Aligned

Clinical Trial Result Secondary Endpoint Mentioned Combination Therapy Mentioned Indication Expansion Lead Asset Progress

Auditor Appointment Ratification

Clinical Trial Result Secondary Endpoint Mentioned Combination Therapy Mentioned Indication Expansion

Ceo Team Pride Statement Board Committee Member Listing Publication Positive Checkpoint Inhibitor Program Interim Data Positive Patient Retention High Priority Review Or Pdufa Disclosed Safety Differentiated Geographic Footprint Disclosure Kol Endorsement Fast Track Designation Received

Cash Flow Statement Investing Activities Financing Activities Cash Flow Disclosure Operating Lease Rent Expense Disclosed Net Loss Reported Fair Value Hierarchy Reconciliation Disclosed Institutional Investment Checkpoint Inhibitor Program Ipo Or Capital Raising Completion Publication Positive Interim Data Positive

Clinical Trial Result Secondary Endpoint Mentioned Indication Expansion Combination Therapy Mentioned Lead Asset Progress

Net Loss Reported Fast Track Granted Fast Track Designation Received Checkpoint Inhibitor Program Expanded Access Program Active Ip Protection Methods Disclosed Interim Data Positive

Combination Therapy Mentioned Clinical Trial Result Indication Expansion Regulatory Designation Only Secondary Endpoint Mentioned

Accelerated Approval

Volume Inflecting Reimbursement Improving